Word

TRANSBIOTICS

Status

Dead

Status Code

606

Status Date

Monday, November 25, 2019

Serial Number

87724721

Mark Type

4000

Filing Date

Monday, December 18, 2017

Published for Opposition

Tuesday, August 28, 2018

Abandoned Date

Monday, November 25, 2019

Trademark Owner History

PEBBLE LABS INC. - 1st New Owner After Publication
Pebble Labs, Inc. - Owner At Publication

Classifications

1 Cultures of microorganisms other than for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Cultures of microorganisms other than for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in plants, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Cultures of microorganisms other than for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in plants, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Probiotic compositions use as ingredients for food and beverages, namely, genetically engineered probiotic bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Probiotic compositions for use as ingredients for food and beverages, namely, genetically modified probiotic bacteria configured to produce bioavailable nutritional compounds; Cultures of microorganisms for medical or agricultural use, namely, genetically modified endophytic bacteria for use in therapeutic treatment of pathogens in plants

5 Cultures of microorganisms for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Biological preparations for the treatment of infectious diseases in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target animal pathogen genes; Biological preparations for the treatment of infectious diseases in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target plant pathogen genes; Biological preparations for the treatment of viral infections in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target viral pathogen genes; Biological preparations for the treatment of bacterial infections in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target bacterial pathogen genes; Biological preparations for the treatment of fungal diseases, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target fungal pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in animals, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Probiotic preparations for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in animals, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified enteric bacteria for use in therapeutic treatment of pathogens in animals; Medical, biological and pharmaceutical preparations for the prevention and treatment of infectious diseases in plants and animals; biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals; Cultures of microorganisms for medical or veterinary use, namely, biological RNA-based therapeutic agents that inhibit the expression of target genes in plant pests and herbivores

Trademark Events

Nov 25, 2019

Abandonment Notice E-Mailed - No Use Statement Filed

Nov 25, 2019

Abandonment - No Use Statement Filed

Oct 9, 2019

Automatic Update Of Assignment Of Ownership

Apr 25, 2019

Notice Of Approval Of Extension Request E-Mailed

Apr 23, 2019

Extension 1 Granted

Apr 23, 2019

Extension 1 Filed

Apr 23, 2019

Teas Extension Received

Oct 23, 2018

Noa E-Mailed - Sou Required From Applicant

Aug 28, 2018

Official Gazette Publication Confirmation E-Mailed

Aug 28, 2018

Published For Opposition

Aug 8, 2018

Notification Of Notice Of Publication E-Mailed

Jul 23, 2018

Approved For Pub - Principal Register

Jul 23, 2018

Examiner's Amendment Entered

Jul 23, 2018

Notification Of Examiners Amendment E-Mailed

Jul 23, 2018

Examiners Amendment E-Mailed

Jul 23, 2018

Examiners Amendment -Written

Jul 2, 2018

Teas/Email Correspondence Entered

Jul 2, 2018

Correspondence Received In Law Office

Jun 28, 2018

Assigned To Lie

Jun 15, 2018

Teas Response To Office Action Received

Mar 30, 2018

Notification Of Non-Final Action E-Mailed

Mar 30, 2018

Non-Final Action E-Mailed

Mar 30, 2018

Non-Final Action Written

Mar 28, 2018

Assigned To Examiner

Jan 4, 2018

New Application Office Supplied Data Entered In Tram

Dec 21, 2017

New Application Entered In Tram